Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Cognition and hospitalizations are linked with salivary and faecal microbiota in cirrhosis cohorts from the USA and Mexico.

Bajaj JS, Torre A, Rojas ML, Fagan A, Nandez IE, Gavis EA, De Leon Osorio O, White MB, Fuchs M, Sikaroodi M, Gillevet PM.

Liver Int. 2020 Mar 17. doi: 10.1111/liv.14437. [Epub ahead of print]

PMID:
32181561
2.

Gut microbiota manipulation during the prepubertal period shapes behavioral abnormalities in a mouse neurodevelopmental disorder model.

Saunders JM, Moreno JL, Ibi D, Sikaroodi M, Kang DJ, Muñoz-Moreno R, Dalmet SS, García-Sastre A, Gillevet PM, Dozmorov MG, Bajaj JS, González-Maeso J.

Sci Rep. 2020 Mar 13;10(1):4697. doi: 10.1038/s41598-020-61635-6.

3.

Optimization of tissue sampling for Borrelia burgdorferi in white-footed mice (Peromyscus leucopus).

Zawada SG, von Fricken ME, Weppelmann TA, Sikaroodi M, Gillevet PM.

PLoS One. 2020 Jan 24;15(1):e0226798. doi: 10.1371/journal.pone.0226798. eCollection 2020.

4.

Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.

Bajaj JS, Salzman N, Acharya C, Takei H, Kakiyama G, Fagan A, White MB, Gavis EA, Holtz ML, Hayward M, Nittono H, Hylemon PB, Cox IJ, Williams R, Taylor-Robinson SD, Sterling RK, Matherly SC, Fuchs M, Lee H, Puri P, Stravitz RT, Sanyal AJ, Ajayi L, Le Guennec A, Atkinson RA, Siddiqui MS, Luketic V, Pandak WM, Sikaroodi M, Gillevet PM.

JCI Insight. 2019 Dec 19;4(24). pii: 133410. doi: 10.1172/jci.insight.133410.

5.

Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis.

Cox IJ, Idilman R, Fagan A, Turan D, Ajayi L, Le Guennec AD, Taylor-Robinson SD, Karakaya F, Gavis E, Andrew Atkinson R, Williams R, Sikaroodi M, Nizam S, Gillevet PM, Bajaj JS.

Liver Int. 2020 Feb;40(2):416-427. doi: 10.1111/liv.14256. Epub 2019 Oct 7.

PMID:
31544308
6.

Posttraumatic stress disorder is associated with altered gut microbiota that modulates cognitive performance in veterans with cirrhosis.

Bajaj JS, Sikaroodi M, Fagan A, Heuman D, Gilles H, Gavis EA, Fuchs M, Gonzalez-Maeso J, Nizam S, Gillevet PM, Wade JB.

Am J Physiol Gastrointest Liver Physiol. 2019 Nov 1;317(5):G661-G669. doi: 10.1152/ajpgi.00194.2019. Epub 2019 Aug 28.

PMID:
31460790
7.

Reply.

Bajaj JS, Gillevet PM.

Gastroenterology. 2019 Sep;157(3):902-903. doi: 10.1053/j.gastro.2019.07.005. Epub 2019 Jul 11. No abstract available.

PMID:
31302141
8.

Gut microbiome identifies risk for colorectal polyps.

Dadkhah E, Sikaroodi M, Korman L, Hardi R, Baybick J, Hanzel D, Kuehn G, Kuehn T, Gillevet PM.

BMJ Open Gastroenterol. 2019 May 27;6(1):e000297. doi: 10.1136/bmjgast-2019-000297. eCollection 2019.

9.

Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant.

Liu R, Kang JD, Sartor RB, Sikaroodi M, Fagan A, Gavis EA, Zhou H, Hylemon PB, Herzog JW, Li X, Lippman RH, Gonzalez-Maeso J, Wade JB, Ghosh S, Gurley E, Gillevet PM, Bajaj JS.

Hepatology. 2020 Feb;71(2):611-626. doi: 10.1002/hep.30827. Epub 2019 Aug 19.

PMID:
31220352
10.

Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.

Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM.

Hepatology. 2019 Nov;70(5):1690-1703. doi: 10.1002/hep.30690. Epub 2019 Jun 18.

PMID:
31038755
11.

Alterations in Skin Microbiomes of Patients With Cirrhosis.

Bajaj JS, Fagan A, Sikaroodi M, Kakiyama G, Takei H, Degefu Y, Pandak WM, Hylemon PB, Fuchs M, John B, Heuman DM, Gavis E, Nittono H, Patil R, Gillevet PM.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2581-2591.e15. doi: 10.1016/j.cgh.2019.03.028. Epub 2019 Mar 21.

PMID:
30905718
12.

Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.

Bajaj JS, Fagan A, White MB, Wade JB, Hylemon PB, Heuman DM, Fuchs M, John BV, Acharya C, Sikaroodi M, Gillevet PM.

Am J Gastroenterol. 2019 Jul;114(7):1080-1090. doi: 10.14309/ajg.0000000000000102.

PMID:
30816877
13.

Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.

Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM.

Gastroenterology. 2019 May;156(6):1921-1923.e3. doi: 10.1053/j.gastro.2019.01.033. Epub 2019 Jan 18. No abstract available.

PMID:
30664879
14.

The Effect of Dietary Mushroom Agaricus bisporus on Intestinal Microbiota Composition and Host Immunological Function.

Solano-Aguilar GI, Jang S, Lakshman S, Gupta R, Beshah E, Sikaroodi M, Vinyard B, Molokin A, Gillevet PM, Urban JF Jr.

Nutrients. 2018 Nov 9;10(11). pii: E1721. doi: 10.3390/nu10111721.

15.

Periodontal therapy favorably modulates the oral-gut-hepatic axis in cirrhosis.

Bajaj JS, Matin P, White MB, Fagan A, Deeb JG, Acharya C, Dalmet SS, Sikaroodi M, Gillevet PM, Sahingur SE.

Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G824-G837. doi: 10.1152/ajpgi.00230.2018. Epub 2018 Aug 17.

16.

Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.

Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM.

Clin Gastroenterol Hepatol. 2019 Mar;17(4):756-765.e3. doi: 10.1016/j.cgh.2018.07.022. Epub 2018 Jul 20.

PMID:
30036646
17.

Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.

Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM.

Am J Gastroenterol. 2018 Aug;113(8):1177-1186. doi: 10.1038/s41395-018-0085-9. Epub 2018 Jun 6.

PMID:
29872220
18.

Reply.

Bajaj JS, Savidge T, Kassam ZA, Hylemon PB, Gillevet PM.

Hepatology. 2018 Sep;68(3):1206. doi: 10.1002/hep.30092. No abstract available.

PMID:
29774575
19.

Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Bajaj JS, Kakiyama G, Savidge T, Takei H, Kassam ZA, Fagan A, Gavis EA, Pandak WM, Nittono H, Hylemon PB, Boonma P, Haag A, Heuman DM, Fuchs M, John B, Sikaroodi M, Gillevet PM.

Hepatology. 2018 Oct;68(4):1549-1558. doi: 10.1002/hep.30037. Epub 2018 Sep 20.

PMID:
29665102
20.

A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients.

Keshteli AH, Tso R, Dieleman LA, Park H, Kroeker KI, Jovel J, Gillevet PM, Sikaroodi M, Mandal R, Fedorak RN, Madsen KL.

Inflamm Bowel Dis. 2018 Mar 19;24(4):861-870. doi: 10.1093/ibd/izx070.

PMID:
29562272
21.

Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.

Bajaj JS, Thacker LR, Fagan A, White MB, Gavis EA, Hylemon PB, Brown R, Acharya C, Heuman DM, Fuchs M, Dalmet S, Sikaroodi M, Gillevet PM.

JCI Insight. 2018 Mar 8;3(5). pii: 98019. doi: 10.1172/jci.insight.98019.

22.

Alterations in gut microbial function following liver transplant.

Bajaj JS, Kakiyama G, Cox IJ, Nittono H, Takei H, White M, Fagan A, Gavis EA, Heuman DM, Gilles HC, Hylemon P, Taylor-Robinson SD, Legido-Quigley C, Kim M, Xu J, Williams R, Sikaroodi M, Pandak WM, Gillevet PM.

Liver Transpl. 2018 Jun;24(6):752-761. doi: 10.1002/lt.25046. Epub 2018 May 13.

23.

Gut microbial composition can differentially regulate bile acid synthesis in humanized mice.

Kang DJ, Hylemon PB, Gillevet PM, Sartor RB, Betrapally NS, Kakiyama G, Sikaroodi M, Takei H, Nittono H, Zhou H, Pandak WM, Yang J, Jiao C, Li X, Lippman HR, Heuman DM, Bajaj JS.

Hepatol Commun. 2017 Feb 27;1(1):61-70. doi: 10.1002/hep4.1020. eCollection 2017 Feb.

24.

Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort.

Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D, White MB, Karakaya F, Wang J, Atalay R, Hylemon PB, Gavis EA, Brown R, Thacker LR, Acharya C, Heuman DM, Sikaroodi M, Gillevet PM.

Hepatology. 2018 Jul;68(1):234-247. doi: 10.1002/hep.29791. Epub 2018 May 10.

PMID:
29350768
25.

Publisher Correction: Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus.

Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B.

Nat Commun. 2017 Dec 12;8(1):2137. doi: 10.1038/s41467-017-01779-8.

26.

Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus.

Llorente C, Jepsen P, Inamine T, Wang L, Bluemel S, Wang HJ, Loomba R, Bajaj JS, Schubert ML, Sikaroodi M, Gillevet PM, Xu J, Kisseleva T, Ho SB, DePew J, Du X, Sørensen HT, Vilstrup H, Nelson KE, Brenner DA, Fouts DE, Schnabl B.

Nat Commun. 2017 Oct 16;8(1):837. doi: 10.1038/s41467-017-00796-x. Erratum in: Nat Commun. 2017 Dec 12;8(1):2137.

27.

Continued Alcohol Misuse in Human Cirrhosis is Associated with an Impaired Gut-Liver Axis.

Bajaj JS, Kakiyama G, Zhao D, Takei H, Fagan A, Hylemon P, Zhou H, Pandak WM, Nittono H, Fiehn O, Salzman N, Holtz M, Simpson P, Gavis EA, Heuman DM, Liu R, Kang DJ, Sikaroodi M, Gillevet PM.

Alcohol Clin Exp Res. 2017 Nov;41(11):1857-1865. doi: 10.1111/acer.13498. Epub 2017 Oct 11.

PMID:
28925102
28.

Reply.

Bajaj JS, Kassam Z, Cox IJ, Gurry T, Williams R, Alm E, John B, Smith M, Taylor-Robinson SD, Gillevet PM.

Hepatology. 2017 Oct;66(4):1355-1356. doi: 10.1002/hep.29368. Epub 2017 Aug 26. No abstract available.

29.

Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.

Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM.

Hepatology. 2017 Dec;66(6):1727-1738. doi: 10.1002/hep.29306. Epub 2017 Oct 30.

30.

Fungal dysbiosis in cirrhosis.

Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM.

Gut. 2018 Jun;67(6):1146-1154. doi: 10.1136/gutjnl-2016-313170. Epub 2017 Jun 3.

PMID:
28578302
31.

Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis.

Bajaj JS, Fagan A, Sikaroodi M, White MB, Sterling RK, Gilles H, Heuman D, Stravitz RT, Matherly SC, Siddiqui MS, Puri P, Sanyal AJ, Luketic V, John B, Fuchs M, Ahluwalia V, Gillevet PM.

Liver Transpl. 2017 Jul;23(7):907-914. doi: 10.1002/lt.24754.

32.

Elevated temperature enhances short- to medium-chain acyl homoserine lactone production by black band disease-associated vibrios.

Bhedi CD, Prevatte CW, Lookadoo MS, Waikel PA, Gillevet PM, Sikaroodi M, Campagna SR, Richardson LL.

FEMS Microbiol Ecol. 2017 Mar 1;93(3). doi: 10.1093/femsec/fix005.

PMID:
28137764
33.

Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis.

Bajaj JS, Ahluwalia V, Steinberg JL, Hobgood S, Boling PA, Godschalk M, Habib S, White MB, Fagan A, Gavis EA, Ganapathy D, Hylemon PB, Stewart KE, Keradman R, Liu EJ, Wang J, Gillevet PM, Sikaroodi M, Moeller FG, Wade JB.

Sci Rep. 2016 Dec 6;6:38481. doi: 10.1038/srep38481.

34.

Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis.

Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS.

Aliment Pharmacol Ther. 2017 Jan;45(2):319-331. doi: 10.1111/apt.13858. Epub 2016 Nov 20.

35.

Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition.

Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS.

Clin Transl Gastroenterol. 2016 Aug 25;7(8):e187. doi: 10.1038/ctg.2016.44.

36.

Gut microbiome and liver disease.

Betrapally NS, Gillevet PM, Bajaj JS.

Transl Res. 2017 Jan;179:49-59. doi: 10.1016/j.trsl.2016.07.005. Epub 2016 Jul 15. Review.

37.

HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.

Bajaj JS, Sterling RK, Betrapally NS, Nixon DE, Fuchs M, Daita K, Heuman DM, Sikaroodi M, Hylemon PB, White MB, Ganapathy D, Gillevet PM.

Aliment Pharmacol Ther. 2016 Sep;44(6):638-43. doi: 10.1111/apt.13732. Epub 2016 Jul 15.

38.

Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, Sanyal AJ, Heuman DM, Carl D, Zhou H, Liu R, Wang X, Yang J, Jiao C, Herzog J, Lippman HR, Sikaroodi M, Brown RR, Bajaj JS.

Hepatology. 2016 Oct;64(4):1232-48. doi: 10.1002/hep.28696. Epub 2016 Jul 29.

39.

Impaired Gut-Liver-Brain Axis in Patients with Cirrhosis.

Ahluwalia V, Betrapally NS, Hylemon PB, White MB, Gillevet PM, Unser AB, Fagan A, Daita K, Heuman DM, Zhou H, Sikaroodi M, Bajaj JS.

Sci Rep. 2016 May 26;6:26800. doi: 10.1038/srep26800.

40.

Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?

Betrapally NS, Gillevet PM, Bajaj JS.

Gastroenterology. 2016 Jun;150(8):1745-1755.e3. doi: 10.1053/j.gastro.2016.02.073. Epub 2016 Mar 4. Review.

41.

Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults.

Miller GE, Engen PA, Gillevet PM, Shaikh M, Sikaroodi M, Forsyth CB, Mutlu E, Keshavarzian A.

PLoS One. 2016 Feb 9;11(2):e0148952. doi: 10.1371/journal.pone.0148952. eCollection 2016.

42.

Erratum: Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.

Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM.

Sci Rep. 2016 Jan 29;6:20447. doi: 10.1038/srep20447. No abstract available.

43.

Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.

Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM.

Sci Rep. 2015 Dec 22;5:18559. doi: 10.1038/srep18559. Erratum in: Sci Rep. 2016;6:20447.

44.

Decompensated cirrhosis and microbiome interpretation.

Bajaj JS, Betrapally NS, Gillevet PM.

Nature. 2015 Sep 17;525(7569):E1-2. doi: 10.1038/nature14851. No abstract available.

45.

High-intensity sweetener consumption and gut microbiome content and predicted gene function in a cross-sectional study of adults in the United States.

Frankenfeld CL, Sikaroodi M, Lamb E, Shoemaker S, Gillevet PM.

Ann Epidemiol. 2015 Oct;25(10):736-42.e4. doi: 10.1016/j.annepidem.2015.06.083. Epub 2015 Jul 17.

PMID:
26272781
46.

Quorum-sensing dysbiotic shifts in the HIV-infected oral metabiome.

Brown RE, Ghannoum MA, Mukherjee PK, Gillevet PM, Sikaroodi M.

PLoS One. 2015 Apr 17;10(4):e0123880. doi: 10.1371/journal.pone.0123880. eCollection 2015.

47.

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.

Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM.

Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.

48.

Temporal Study of the Microbial Diversity of the North Arm of Great Salt Lake, Utah, U.S.

Almeida-Dalmet S, Sikaroodi M, Gillevet PM, Litchfield CD, Baxter BK.

Microorganisms. 2015 Jul 2;3(3):310-26. doi: 10.3390/microorganisms3030310.

49.

Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.

Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, Hylemon PB, White MB, Daita K, Noble NA, Sikaroodi M, Williams R, Crossey MM, Taylor-Robinson SD, Gillevet PM.

Am J Physiol Gastrointest Liver Physiol. 2014 Nov 15;307(10):G951-7. doi: 10.1152/ajpgi.00268.2014. Epub 2014 Sep 25.

50.

A single macrolichen constitutes hundreds of unrecognized species.

Lücking R, Dal-Forno M, Sikaroodi M, Gillevet PM, Bungartz F, Moncada B, Yánez-Ayabaca A, Chaves JL, Coca LF, Lawrey JD.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11091-6. doi: 10.1073/pnas.1403517111. Epub 2014 Jun 30.

Supplemental Content

Loading ...
Support Center